search icon
      blog search icon

      Cocrystal Pharma Inc. (COCP) stock surged during pre-market trading. Here’s what happened? - Stocks Telegraph

      By Mahnoor Shah

      Published on

      December 2, 2021

      9:55 AM UTC

      Cocrystal Pharma Inc. (COCP) stock surged during pre-market trading. Here’s what happened? - Stocks Telegraph

      Cocrystal Pharma Inc. (NASDAQ: COCP) stock fell by 6.42% at last close whereas the COCP stock price gained by 1.19% in the pre-market trading session. Cocrystal Pharma is a clinical-stage biotechnology firm focused on researching and developing innovative antiviral treatments that address coronaviruses (particularly SARS-CoV-2), influenza viruses, hepatitis C virus, and norovirus replication.

      COCP stock’ Current Update

      At the World Antiviral Congress 2021 in San Diego, Cocrystal Pharma presented positive preclinical data from its COVID-19 programs and discussed its clinical ambitions to progress two antiviral medicines. “Discovery of Oral, Broad-Spectrum SARS-CoV-2 Mpro Inhibitors: Advancing to Clinical Development,” by Cocrystal President and Co-Interim CEO Sam Lee, Ph.D., is published here.

      Dr. Lee’s talk focused on the benefits of Cocrystal’s structure-based drug discovery platform technology for developing innovative broad-spectrum antiviral leads, which are currently being developed for COVID-19, influenza, and norovirus. He presented the in vitro and in vivo features of Cocrystal’s intranasal and oral major protease (Mpro) inhibitors, as well as the company’s clinical development intentions, as part of the COVID-19 programs.

      In his presentation, Dr. Lee stated that,

      Their focus is to create numerous broad-spectrum antivirals for the cure of COVID-19 that can be taken orally, intranasally, or intravenously. They also think that a COVID-19 antiviral’s wide spectrum coverage against Delta, the most common SARS-CoV-2 variant, and newly developing variants like Omicron is critical. In vitro, our SARS-CoV-2 protease inhibitors demonstrated wide antiviral efficacy against Alpha, Beta, Delta, and Gamma variants. Their high-resolution cocrystal structures, created with their proprietary platform technology, backed up these findings.


      Clinical trial designs for CDI-45205, an intranasal lead, and its oral SARS-CoV-2 inhibitors were also revealed by Cocrystal. The Phase 1 study in healthy subjects will be a randomized, placebo-controlled, double-blind, single-ascending-dose/multiple-ascending-dose experiment to assess safety, tolerability, pharmacokinetics, and the influence of food. The Phase 2 trial will be a randomized, double-blind, placebo-controlled trial in individuals with mild or moderate COVID-19 who are not hospitalized, with viral load change as the primary end measure. The FDA’s reaction to Cocrystal’s CDI-45205 pre-IND briefing package submission is still pending.

      More From Stocks telegraph